Hindu Business Line | US group opposes Gilead's patenting of hepatitis C drug in India domain-B US drug-maker Gilead Sciences' patent application on hepatitis C drug sofosbuvir in India is facing opposition from a US legal group I-MAK (Initiative for Medicines, Access & Knowledge) on the ground that it is old known compound and has nothing new to ... US group seeks to block Gilead drug patent in India US group against Gilead's patent request in India for hepatitis C drug Indian health activists move to prevent Gilead's drug patent |
